<DOC>
	<DOCNO>NCT00955760</DOCNO>
	<brief_summary>Primary Objectives : • Assess effect poly-specific cytochrome P450 drug-transporter induction repeat dose Rifampicin ( 600 mg/day ) co-administration single-dose pharmacokinetics Neramexane . Secondary Objectives : • To assess safety tolerability Neramexane single dose treatment alone co-administration Neramexane single dose Rifampicin repeat dose treatment .</brief_summary>
	<brief_title>Study Analyzing Effect Rifampicin Administration Pharmacokinetics Neramexane Mesylate</brief_title>
	<detailed_description />
	<mesh_term>Rifampin</mesh_term>
	<criteria>Healthy adult subject , able read , write fully understand German language Aged 18 45 year ( inclusive ) BMI 1828 kg/m2 ( inclusive ) body weight 5090 kg ( inclusive ) Willing able provide write informed consent inform requirement restriction study Female subject childbearing potential must agree use highly effective method birth control define result low failure rate ( i.e. , less 1 % per year ) use consistently correctly sexual abstinence , vasectomise partner , non hormonal IUDs , double barrier method , e.g. , condom spermicide cream Safety concern History clinically relevant allergy know hypersensitivity Neramexane/Memantine/Amantadine derivatives History clinically relevant allergy know hypersensitivity Rifampicin rifamycines History clinically relevant allergy know hypersensitivity inactive ingredient use investigational product metabolic inducer Exposure another investigational agent within last two month Day 1 Period 1 Lactating pregnant female female plan become pregnant study conduct within 2 month end study . Males plan beget child study conduct within 2 month end study Any contraindication indicate topically valid SPC EREMFAT® : severe hepatic impairment like obstructive jaundice , hepatitis , hepatic cirrhosis Lack suitability trial Any evidence significant cardiovascular , pulmonary , renal , hepatic , gastrointestinal , endocrinological , metabolic disease screen History malignancy Any clinically relevant deviation clinical laboratory assessment ECG abnormalities clinical relevance , particular abnormal prolongation QT/QTcinterval ( i.e. , QTc ≥ 450 m , PQ ≥ 220 m ) Systolic blood pressure &lt; 95 mmHg &gt; 150 mmHg diastolic blood pressure &lt; 50 mmHg &gt; 90 mmHg supine position Pulse rate &lt; 45 &gt; 100 beat per minute Chronic acute clinically relevant infection Chronic acute disease , especially psychiatric neurologic disorder History alcohol drug dependence Alcohol consumption average 40 g male 20 g female subject daily within last year Regular caffeine consumption average 1 L coffee and/or tea daily 1 L caffeinecontaining lemonade per day within last year Disorders surgery gastrointestinal tract may interfere drug absorption may otherwise influence pharmacokinetics investigational medicinal product ( e.g. , cholecystectomy , ulcus , etc . ) Use prescribed medication four week prior first administration IMP . Regular use overthecounter drug [ OTC ] 4 week prior first administration IMP Occasional use OTC drug ( except paracetamol , maximum 1 g/day ) within 2 week prior first administration IMP . Stable intake thyroid hormone substitution allow . Use food , food supplement medication know induce inhibit CYP3A4 cytochrome P450 enzymes within two week precede start study ( Day 1 ) , e.g . grapefruit , St. John 's wort Female subject employ form hormonal contraception within 2 month prior study Day 1 ( e.g . oral contraceptive , hormone release intrauterine contraceptive device [ IUDs ] , etc . ) Consumption xanthine derivates ( include caffeine ) within two day prior Day 1 Smoker user snuff , nicotine replacement chew tobacco Previous enrollment clinical phase current study Positive result serology test Blood donation 450 mL within 60 day prior Day 1 Positive pregnancy test , female Positive drug screen alcohol test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Healthy subject</keyword>
</DOC>